Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)799.29K
Market Cap
$591.14M
Enterprise Value$575.69M
Total Cash (Recent Filing)$22.19M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2025EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding29,380,495
10 Day Avg. Volume469,134
30 Day Avg. Volume799,290
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.21
Forecast
1Y Price Target
$44.13Price Target Upside124.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
AnaptysBio News
---
Bulls Say, Bears Say
Bulls Say
Drug Development SuccessThe Ph. II trial of rosnilimab in RA hit the primary endpoint and demonstrated benefit on key secondary endpoints.
Financial CollaborationGSK reported Jemperli sales significantly above the consensus, which is positive for ANAB due to their financial collaboration.
Share Repurchase PlanANAB announced plans to repurchase up to $75M in shares, which represents roughly 12% of the primary shares outstanding.
Bears Say
Competitive PressureShares were pressured following LLY's termination of its PD-1 agonist program in RA.
Placebo Response ChallengeThere was a higher than anticipated placebo response in the ANB032 trial, which did not meet the expected targets.
Trial DiscontinuationANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
---
Ownership Overview
43.85% Insiders
21.76% Mutual Funds
0.91% Other Institutional Investors
22.15% Public Companies and
Individual Investors
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $591.14M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 11, 2025 which is in 94 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 05, 2025. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.253 by -$0.027.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.5.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 29,380,495 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.253. Following the earnings report the stock price went down -2.943%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
---
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.13 (124.24% Upside)
$44.13 (124.24% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.92%
12-Months-Change
Fundamentals
Return on Equity
-343.83%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
---
ANAB Stock 12 Month Forecast
Average Price Target
$44.13
▲(124.24% Upside)
Technical Analysis
---